THERALINK TECHNOLOGIES, INC.

$ Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315224007204 Filed on February 20, 2024

Income Statement

Concept	2023 Q4	2022 Q4

Balance Sheet

Concept	2023 Q4	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$24.27K	$1.133M
YoY Change	-97.86%	162.55%
Cash & Equivalents	$23.77K	$1.131M
Short-Term Investments	$500.00	$1.700K
Other Short-Term Assets	$186.6K	$197.7K
YoY Change	-5.61%	-25.1%
Inventory
Prepaid Expenses
Receivables	$45.78K	$48.30K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$256.7K	$1.379M
YoY Change	-81.38%	78.89%
LONG-TERM ASSETS
Property, Plant & Equipment	$409.8K	$655.2K
YoY Change	-37.46%	-66.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$15.26K	$18.72K
YoY Change	-18.48%	-10.47%
Total Long-Term Assets	$1.528M	$1.870M
YoY Change	-18.29%	-5.39%
TOTAL ASSETS
Total Short-Term Assets	$256.7K	$1.379M
Total Long-Term Assets	$1.528M	$1.870M
Total Assets	$1.784M	$3.248M
YoY Change	-45.06%	18.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.429M	$675.4K
YoY Change	111.61%	-23.53%
Accrued Expenses	$4.064M	$156.9K
YoY Change	2489.69%	-68.11%
Deferred Revenue	$141.3K	$177.1K
YoY Change	-20.2%
Short-Term Debt	$1.159M	$351.0K
YoY Change	230.25%	247.52%
Long-Term Debt Due	$21.45M	$1.500M
YoY Change	1329.68%	2947.68%
Total Short-Term Liabilities	$57.79M	$46.38M
YoY Change	24.6%	1354.67%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$23.47K
YoY Change	-100.0%	-90.51%
Other Long-Term Liabilities	$1.117M	$1.150M
YoY Change	-2.86%	-2.29%
Total Long-Term Liabilities	$1.117M	$1.174M
YoY Change	-4.8%	-17.6%
TOTAL LIABILITIES
Total Short-Term Liabilities	$57.79M	$46.38M
Total Long-Term Liabilities	$1.117M	$1.174M
Total Liabilities	$58.90M	$47.55M
YoY Change	23.87%	930.84%
SHAREHOLDERS EQUITY
Retained Earnings	-$112.8M	-$99.30M
YoY Change	13.59%
Common Stock	$615.2K	$615.2K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$57.10M	-$44.30M
YoY Change
Total Liabilities & Shareholders Equity	$1.784M	$3.248M
YoY Change	-45.06%	18.25%

Cashflow Statement

Concept	2023 Q4	2022 Q4

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2023Q4	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q4	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q4	dei	Entity Central Index Key EntityCentralIndexKey	0001362703
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q4	us-gaap	Litigation Settlement Expense LitigationSettlementExpense		usd
CY2023Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q4	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2022Q4	us-gaap	Litigation Settlement Interest LitigationSettlementInterest		usd
CY2023Q4	us-gaap	Litigation Settlement Expense LitigationSettlementExpense		usd
CY2023Q4	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023Q4	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2023Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2023Q4	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2023Q4	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q4	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q4	THER	Preferred Stock Dividend One PreferredStockDividendOne		usd
CY2023Q4	THER	Preferred Stock Dividend Two PreferredStockDividendTwo		usd
CY2023Q4	THER	Initial Fair Value Of Derivative Liabilities Recorded As Debt Discount Related Parties InitialFairValueOfDerivativeLiabilitiesRecordedAsDebtDiscountRelatedParties		usd
CY2023Q4	THER	Initial Fair Value Of Derivative Liabilities Recorded As Debt Discount InitialFairValueOfDerivativeLiabilitiesRecordedAsDebtDiscount		usd
CY2023Q4	THER	Exchange Of Preferred Stock And Accrued Dividends For Convertible Debt Related Parties ExchangeOfPreferredStockAndAccruedDividendsForConvertibleDebtRelatedParties		usd
CY2023Q4	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1		usd
CY2023Q4	THER	Exchange Of Accrued Interest Payable For Convertible Debt Related Parties ExchangeOfAccruedInterestPayableForConvertibleDebtRelatedParties		usd
CY2023Q4	THER	Exchange Of Accrued Interest Payable For Convertible Debt ExchangeOfAccruedInterestPayableForConvertibleDebt		usd
CY2023Q4	THER	Billings And Cash Receipts On Uncompleted Contract BillingsAndCashReceiptsOnUncompletedContract		usd
CY2022Q4	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount		usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2023Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2023Q4	THER	Debt Instrument Unamortized Discount Related Party DebtInstrumentUnamortizedDiscountRelatedParty		usd
CY2023Q4	THER	Convertible Debt Related Party Non Current ConvertibleDebtRelatedPartyNonCurrent		usd
CY2023Q3	THER	Convertible Debt Related Party Non Current ConvertibleDebtRelatedPartyNonCurrent		usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q4	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q4	dei	Document Type DocumentType	10-Q
CY2023Q4	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q4	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023Q4	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q4	dei	Entity File Number EntityFileNumber	000-52218
CY2023Q4	dei	Entity Registrant Name EntityRegistrantName	Theralink Technologies, Inc.
CY2023Q4	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q4	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-2590810
CY2023Q4	dei	Entity Address Address Line1 EntityAddressAddressLine1	15000 W. 6th Avenue
CY2023Q4	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 400
CY2023Q4	dei	Entity Address City Or Town EntityAddressCityOrTown	Golden
CY2023Q4	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
CY2023Q4	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80401
CY2023Q4	dei	City Area Code CityAreaCode	(720)
CY2023Q4	dei	Local Phone Number LocalPhoneNumber	420-0074
CY2023Q4	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q4	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q4	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q4	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q4	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q4	dei	Entity Shell Company EntityShellCompany	false
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6151499919	shares
CY2023Q4	us-gaap	Cash Cash	23770	usd
CY2023Q3	us-gaap	Cash Cash	997484	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	45780	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23910	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	186621	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	240494	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	500	usd
CY2023Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	800	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	256671	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	1262688	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	409805	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	448515	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	11382	usd
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	18988	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1091384	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1104346	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	15257	usd
CY2023Q3	us-gaap	Security Deposit SecurityDeposit	15257	usd
CY2023Q4	us-gaap	Assets Assets	1784499	usd
CY2023Q3	us-gaap	Assets Assets	2849794	usd
CY2023Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	233625	usd
CY2023Q3	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	93845	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	267500	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	252500	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	141290	usd
CY2023Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	144890	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	23469	usd
CY2023Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	30262	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	32939	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	31388	usd
CY2023Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	86553	usd
CY2023Q3	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	121500	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	29371380	usd
CY2023Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	16426304	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	87440	usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	85640	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	57785003	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	39834854	usd
CY2023Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4128	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1117485	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1126373	usd
CY2023Q4	us-gaap	Liabilities Liabilities	58902488	usd
CY2023Q3	us-gaap	Liabilities Liabilities	40965355	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	26667	shares
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	26667	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6151499919	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6151499919	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6151499919	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6151499919	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	615150	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	615150	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	55068273	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	55024063	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-112801412	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93754774	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-57117989	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-38115561	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1784499	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2849794	usd
CY2023Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	83949	usd
CY2022Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	55295	usd
CY2023Q4	us-gaap	Cost Of Revenue CostOfRevenue	52947	usd
CY2022Q4	us-gaap	Cost Of Revenue CostOfRevenue	10818	usd
CY2023Q4	us-gaap	Gross Profit GrossProfit	31002	usd
CY2022Q4	us-gaap	Gross Profit GrossProfit	44477	usd
CY2023Q4	us-gaap	Professional Fees ProfessionalFees	511277	usd
CY2022Q4	us-gaap	Professional Fees ProfessionalFees	387438	usd
CY2023Q4	us-gaap	Share Based Compensation ShareBasedCompensation	752974	usd
CY2022Q4	us-gaap	Share Based Compensation ShareBasedCompensation	1752699	usd
CY2023Q4	THER	Licensing Fees LicensingFees	32710	usd
CY2022Q4	THER	Licensing Fees LicensingFees	31637	usd
CY2023Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	281100	usd
CY2022Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	448493	usd
CY2023Q4	us-gaap	Operating Expenses OperatingExpenses	1578061	usd
CY2022Q4	us-gaap	Operating Expenses OperatingExpenses	2620267	usd
CY2023Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-1547059	usd
CY2022Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-2575790	usd
CY2023Q4	us-gaap	Interest Expense InterestExpense	4554203	usd
CY2022Q4	us-gaap	Interest Expense InterestExpense	1847035	usd
CY2022Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-5434447	usd
CY2023Q4	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-300	usd
CY2022Q4	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-2000	usd
CY2022Q4	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	200000	usd
CY2023Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-12945076	usd
CY2022Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-26397075	usd
CY2023Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-17499579	usd
CY2022Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-33880557	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-19046638	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-36456347	usd
CY2023Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19046638	usd
CY2022Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-36495799	usd
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.00
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6151499919	shares
CY2023Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6151499919	shares
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6151499846	shares
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6151499846	shares
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-38115561	usd
CY2023Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	44210	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-19046638	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-57117989	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-6801055	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-6801055	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	612173	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	-1618238	usd
CY2022Q4	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	26301	usd
CY2022Q4	us-gaap	Dividends Sharebased Compensation Stock DividendsSharebasedCompensationStock	13151	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-36456347	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-44302919	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-44302919	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-19046638	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-36456347	usd
CY2023Q4	us-gaap	Depreciation Depreciation	46316	usd
CY2022Q4	us-gaap	Depreciation Depreciation	50479	usd
CY2023Q4	THER	Non Cash Lease Cost NonCashLeaseCost	5625	usd
CY2022Q4	THER	Non Cash Lease Cost NonCashLeaseCost	6514	usd
CY2023Q4	us-gaap	Accretion Expense AccretionExpense	44210	usd
CY2022Q4	us-gaap	Accretion Expense AccretionExpense	612173	usd
CY2023Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3017093	usd
CY2022Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1602646	usd
CY2022Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-5434447	usd
CY2023Q4	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	31500	usd
CY2023Q4	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-300	usd
CY2022Q4	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-2000	usd
CY2023Q4	us-gaap	Litigation Settlement Interest LitigationSettlementInterest	995280	usd
CY2022Q4	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	200000	usd
CY2023Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-12945076	usd
CY2022Q4	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-26397075	usd
CY2023Q4	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	53370	usd
CY2022Q4	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	16170	usd
CY2023Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-53873	usd
CY2022Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-19976	usd
CY2023Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	200005	usd
CY2022Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-65788	usd
CY2023Q4	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	801537	usd
CY2022Q4	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	416146	usd
CY2023Q4	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3600	usd
CY2022Q4	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	20500	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-962793	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1776349	usd
CY2022Q4	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7980	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7980	usd
CY2022Q4	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	536562	usd
CY2022Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2118088	usd
CY2022Q4	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	120000	usd
CY2023Q4	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	10921	usd
CY2022Q4	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	12879	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-10921	usd
CY2022Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2521771	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-973714	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	737442	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	997484	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	393460	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	23770	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1130902	usd
CY2023Q4	us-gaap	Interest Paid Net InterestPaidNet	22697	usd
CY2022Q4	us-gaap	Interest Paid Net InterestPaidNet	3574	usd
CY2022Q4	THER	Preferred Stock Dividend One PreferredStockDividendOne	26301	usd
CY2022Q4	THER	Preferred Stock Dividend Two PreferredStockDividendTwo	13151	usd
CY2022Q4	THER	Initial Fair Value Of Derivative Liabilities Recorded As Debt Discount Related Parties InitialFairValueOfDerivativeLiabilitiesRecordedAsDebtDiscountRelatedParties	8837284	usd
CY2022Q4	THER	Initial Fair Value Of Derivative Liabilities Recorded As Debt Discount InitialFairValueOfDerivativeLiabilitiesRecordedAsDebtDiscount	7231893	usd
CY2022Q4	THER	Exchange Of Preferred Stock And Accrued Dividends For Convertible Debt Related Parties ExchangeOfPreferredStockAndAccruedDividendsForConvertibleDebtRelatedParties	3099945	usd
CY2022Q4	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	1615238	usd
CY2022Q4	THER	Exchange Of Accrued Interest Payable For Convertible Debt Related Parties ExchangeOfAccruedInterestPayableForConvertibleDebtRelatedParties	129079	usd
CY2022Q4	THER	Exchange Of Accrued Interest Payable For Convertible Debt ExchangeOfAccruedInterestPayableForConvertibleDebt	173375	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-19046638	usd
CY2023Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-962793	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-112800000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-57100000	usd
CY2023Q4	THER	Working Capital Deficit WorkingCapitalDeficit	57500000	usd
CY2023Q4	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_zdT11YFG4Kof" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zwgpaBWCs6Yd">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, assumptions, and estimates that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Management bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. Significant estimates during the three months ended December 31, 2023 and 2022 include, but are not necessarily limited to, estimates of contingent liabilities, valuation of marketable securities, useful life of property and equipment, valuation of right-of-use (“ROU”) assets and lease liabilities, assumptions used in assessing impairment of long-lived assets, allowances for accounts receivable, estimates of current and deferred income taxes and deferred tax valuation allowances, the fair value of derivative liabilities, and the fair value of non-cash equity transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-3600	usd
CY2023Q4	us-gaap	Revenues Revenues	3600	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q4	THER	Cash Fdic Insured Amount Limit CashFDICInsuredAmountLimit	250000	usd
CY2023Q3	THER	Cash Fdic Insured Amount Limit CashFDICInsuredAmountLimit	250000	usd
CY2023Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	747601	usd
CY2023Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	83949	usd
CY2022Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	55295	usd
CY2023Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	144890	usd
CY2022Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	156550	usd
CY2022Q4	THER	Billings And Cash Receipts On Uncompleted Contract BillingsAndCashReceiptsOnUncompletedContract	24000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-3600	usd
CY2022Q4	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-3500	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	141290	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	177050	usd
CY2023Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	0	usd
CY2022Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	0	usd
CY2023Q4	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zqVic7bbfS8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z07BYek4dW4i">Concentrations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentration of Revenues</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 32.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three months ended December 31, 2023, the Company generated total revenue of $<span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20231001__20231231_z7P93IA7E4d1" title="Revenue">83,949</span> of which <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20231001__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zISWcXSumNl9" title="Concentration risk, percentage">13.5</span>% were from one of the Company’s customers. For the three months ended December 31, 2022, the Company generated total revenue of $<span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20221001__20221231_zlFiebCuPpP3" title="Revenue">55,295</span> of which <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20221001__20221231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zfP37ULDmSyb" title="Concentration risk, percentage">72</span>% was from one of the Company’s customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentration of Accounts Receivable</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 32.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the Company had net accounts receivable of $<span id="xdx_905_eus-gaap--AccountsReceivableNetCurrent_iI_pp0p0_c20231231_zfVorQnWgwy5" title="Accounts receivable">45,780</span> of which <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20231001__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zmzlE45FM4L5" title="Concentration risk, percentage">57.9</span>% were from one of the Company’s customers and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20231001__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerMember_zSa88TTg1e2c" title="Concentration risk, percentage">42.1</span>% was from the Company’s self-pay customers. As of September 30, 2023, the Company had net accounts receivable of $<span id="xdx_908_eus-gaap--AccountsReceivableNetCurrent_iI_pp0p0_c20230930_zW7wGQu52mz7" title="Accounts receivable">23,910</span> of which <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20221001__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zU6mzcgAAYaa" title="Concentration risk, percentage">63</span>% was from one of the Company’s customers and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20221001__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerMember_zRQogl8yIoie" title="Concentration risk, percentage">37</span>% was from the Company’s self-pay customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentration of Contract Liabilities</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 32.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, the Company had deferred revenue reflected as contract liabilities of $<span id="xdx_90B_eus-gaap--DeferredRevenue_iI_pp0p0_c20231231_zkQzeAnT1Qm3" title="Deferred revenue">141,290</span> of which <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20231001__20231231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DeferredRevenueMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zHEGuisjZWhi" title="Concentration risk, percentage">100</span>% was from one of the Company’s customers. As of September 30, 2023, the Company had deferred revenue reflected as contract liabilities of $<span id="xdx_90F_eus-gaap--DeferredRevenue_iI_pp0p0_c20230930_zTchJ7rwWCl2" title="Deferred revenue">144,890</span> of which <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20221001__20230930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DeferredRevenueMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zuAlJ8oK0t82" title="Concentration risk, percentage">100</span>% was from one of the Company’s customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	83949	usd
CY2022Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	55295	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	45780	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23910	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	141290	usd
CY2023Q3	us-gaap	Deferred Revenue DeferredRevenue	144890	usd
CY2023Q4	THER	Convertible Debt Related Party Current ConvertibleDebtRelatedPartyCurrent	11942653	usd
CY2023Q3	THER	Convertible Debt Related Party Current ConvertibleDebtRelatedPartyCurrent	9930817	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	21422677	usd
CY2023Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	33366296778	shares
CY2022Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17529476725	shares
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2023Q4	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2023Q4	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-300	usd
CY2022Q4	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-2000	usd
CY2023Q4	us-gaap	Marketable Securities MarketableSecurities	500	usd
CY2023Q3	us-gaap	Marketable Securities MarketableSecurities	800	usd
CY2023Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	89530	usd
CY2023Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	46660	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	43750	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	22750	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	45780	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	23910	usd
CY2023Q4	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	31500	usd
CY2023Q3	THER	Convertible Debt Related Party ConvertibleDebtRelatedParty	9930817	usd
CY2023Q4	THER	Laboratory Equipment LaboratoryEquipment	513788	usd
CY2023Q3	THER	Laboratory Equipment LaboratoryEquipment	513788	usd
CY2023Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	24567	usd
CY2023Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	24567	usd
CY2023Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	353826	usd
CY2023Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	353826	usd
CY2023Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	76469	usd
CY2023Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	76469	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	968650	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	968650	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	558845	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	520135	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	409805	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	448515	usd
CY2023Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	38710	usd
CY2022Q4	us-gaap	Depreciation And Amortization DepreciationAndAmortization	38887	usd
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	9480024	usd
CY2023Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	8986605	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1498388	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	9480024	usd
CY2023Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	7488217	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	9480024	usd
CY2023Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	7488217	usd
CY2023Q4	THER	Debt Instrument Face Amount Related Party DebtInstrumentFaceAmountRelatedParty	11942653	usd
CY2023Q3	THER	Debt Instrument Face Amount Related Party DebtInstrumentFaceAmountRelatedParty	11440792	usd
CY2023Q3	THER	Debt Instrument Unamortized Discount Related Party DebtInstrumentUnamortizedDiscountRelatedParty	1509975	usd
CY2023Q4	THER	Convertible Debt Related Party ConvertibleDebtRelatedParty	11942653	usd
CY2023Q3	us-gaap	Convertible Debt ConvertibleDebt	17419034	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	250000	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	200000	usd
CY2022Q4	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	200000	usd
CY2023Q1	THER	Agreement Description AgreementDescription	Pursuant to the terms of the Placement Agency Agreement, the Company agreed to (i) pay Gunnar a cash placement fee of 10% of the gross cash proceeds raised in the Second Offering, and (ii) issue to Gunnar additional PA Warrants on the terms identical to the Warrants sold in the Second Offering in an amount equal to 10% of the New Debentures sold to Second Closing Purchasers
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	250000	usd
CY2023Q4	THER	Amortization Of Debt Discount Related To Convertible Notes Payable AmortizationOfDebtDiscountRelatedToConvertibleNotesPayable	3008363	usd
CY2022Q4	THER	Amortization Of Debt Discount Related To Convertible Notes Payable AmortizationOfDebtDiscountRelatedToConvertibleNotesPayable	1602646	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	231841	usd
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	231841	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	220459	usd
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	212853	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	11382	usd
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	18988	usd
CY2023Q4	THER	Amortization Expense Financing Right Of Use Asset AmortizationExpenseFinancingRightOfUseAsset	7606	usd
CY2022Q4	THER	Amortization Expense Financing Right Of Use Asset AmortizationExpenseFinancingRightOfUseAsset	11592	usd
CY2023Q4	THER	Financing Lease Payables For Equipment FinancingLeasePayablesForEquipment	231841	usd
CY2023Q3	THER	Financing Lease Payables For Equipment FinancingLeasePayablesForEquipment	231841	usd
CY2023Q4	THER	Financing Lease Payables FinancingLeasePayables	231841	usd
CY2023Q3	THER	Financing Lease Payables FinancingLeasePayables	231841	usd
CY2023Q4	THER	Payments Of Financing Lease Liabilities PaymentsOfFinancingLeaseLiabilities	-208372	usd
CY2023Q3	THER	Payments Of Financing Lease Liabilities PaymentsOfFinancingLeaseLiabilities	-197451	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	23469	usd
CY2023Q3	us-gaap	Finance Lease Liability FinanceLeaseLiability	34390	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	23469	usd
CY2023Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	30262	usd
CY2023Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	4128	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	23677	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	23677	usd
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	208	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	23469	usd
CY2023Q4	us-gaap	Operating Lease Cost OperatingLeaseCost	51208	usd
CY2022Q4	us-gaap	Operating Lease Cost OperatingLeaseCost	50311	usd
CY2023Q4	THER	Operating Office Lease Liability OperatingOfficeLeaseLiability	1212708	usd
CY2023Q3	THER	Operating Office Lease Liability OperatingOfficeLeaseLiability	1212708	usd
CY2023Q4	THER	Operating Lease Right Of Use Asset Accumulated Reduction OperatingLeaseRightOfUseAssetAccumulatedReduction	-121324	usd
CY2023Q3	THER	Operating Lease Right Of Use Asset Accumulated Reduction OperatingLeaseRightOfUseAssetAccumulatedReduction	-108362	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1091384	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1104346	usd
CY2023Q4	THER	Operating Office Lease Liability OperatingOfficeLeaseLiability	1212708	usd
CY2023Q3	THER	Operating Office Lease Liability OperatingOfficeLeaseLiability	1212708	usd
CY2023Q4	THER	Operating Lease Liabilities OperatingLeaseLiabilities	1212708	usd
CY2023Q3	THER	Operating Lease Liabilities OperatingLeaseLiabilities	1212708	usd
CY2023Q4	THER	Reduction Of Operating Lease Liability ReductionOfOperatingLeaseLiability	-62284	usd
CY2023Q3	THER	Reduction Of Operating Lease Liability ReductionOfOperatingLeaseLiability	-54947	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1150424	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1157761	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	32939	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	31388	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1117485	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1126373	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	123806	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	127520	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	131871	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	136177	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	140262	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1238901	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1898537	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	748113	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1150424	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	1069974	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	1099974	usd
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	12000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	0	usd
CY2023Q3	us-gaap	Dividends Payable Current DividendsPayableCurrent	0	usd
CY2023Q4	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	0	usd
CY2023Q3	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	0	usd
CY2023Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	44210	usd
CY2022Q4	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	612173	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	1660670920	shares
CY2023Q4	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1580574866	shares
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	121473	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1664270920	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.0036
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	3600000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.0036
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1660670920	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.0036
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1580574866	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.0036
CY2023Q4	THER	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePrice	0.0036
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1660670920	shares
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y7M17D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.0036
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1580574866	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.0036
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	16393443	shares
CY2023Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	1069974	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	1099974	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	267500	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	252500	usd
CY2020Q3	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	3000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	87440	usd
CY2023Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	85640	usd
CY2023Q4	us-gaap	Notes Payable NotesPayable	40000	usd
CY2023Q3	us-gaap	Notes Payable NotesPayable	40000	usd
CY2023Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	47440	usd
CY2023Q3	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	45640	usd
CY2021Q4	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	100000000	usd
CY2023Q3	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	87000	usd
CY2023Q4	us-gaap	Loss Contingency Settlement Agreement Terms LossContingencySettlementAgreementTerms	The Settlement Payment is payable as follows: (a) $25,000 was due and paid upon the Effective Date of the Settlement Agreement; (b) $62,000 shall be payable in three equal monthly installments as follows: (i) $20,666.67 due and paid on before October 31, 2023; (ii) $20,666.67 due on or before November 30, 2023 (iii) $20,666.67 due on or before December 31, 2023. As of December 31, 2023 and September 30, 2023, the settlement amount of $62,000 was included in accounts payable on the accompanying balance sheets.
CY2017Q3	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	200000	shares
CY2017Q3	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares	2000	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001

Files In Submission

Name	View Source	Status
0001493152-24-007204-index-headers.html	Edgar Link	pending
0001493152-24-007204-index.html	Edgar Link	pending
0001493152-24-007204.txt	Edgar Link	pending
0001493152-24-007204-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ther-20231231.xsd	Edgar Link	pending
ther-20231231_def.xml	Edgar Link	unprocessable
ther-20231231_lab.xml	Edgar Link	unprocessable
ther-20231231_pre.xml	Edgar Link	unprocessable
ther-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

THERALINK TECHNOLOGIES, INC.

2023 Q4 Form 10-Q Financial Statement

#000149315224007204 Filed on February 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission